136 related articles for article (PubMed ID: 29348764)
1. Study on the Clinical Safe and Effective Methods of Arsenic-Containing Compound-Qinghuang Powder in the Treatment of Myelodysplastic Syndrome.
Zhu Q; Deng Z; Zhu S; Zhao P; Wang M; Hu X
Evid Based Complement Alternat Med; 2017; 2017():2095682. PubMed ID: 29348764
[TBL] [Abstract][Full Text] [Related]
2. Relation of Blood Arsenic Concentration with Effect and Safety of Arsenic-Containing Qinghuang Powder () in Patients with Myelodysplastic Syndrome.
Deng ZY; Zhu SR; Wang MJ; Fang S; Zhao P; Zhu QZ; Wang HZ; Guo XQ; Xu YG; Yi BW; Shang XH; Ma R; Hu XM
Chin J Integr Med; 2019 Jul; 25(7):497-501. PubMed ID: 31278627
[TBL] [Abstract][Full Text] [Related]
3. Oral Arsenic-Containing Qinghuang Powder: A Potential Drug for Myelodysplastic Syndromes.
Ming J; Liu WY; Xiao HY; Xu YG; Ma R; Hu XM
Chin J Integr Med; 2022 Aug; 28(8):762-768. PubMed ID: 32146594
[TBL] [Abstract][Full Text] [Related]
4. Effect of Qinghuang Powder () Combined with Bupi Yishen Decoction () in Treating Patients with Refractory Cytopenia with Multilineage Dysplasia through Regulating DNA Methylation.
Zhou QB; Yang XH; Wang HZ; Wang DX; Xu YG; Hu XM; Xu FQ; Ma R
Chin J Integr Med; 2019 May; 25(5):354-359. PubMed ID: 29500545
[TBL] [Abstract][Full Text] [Related]
5. [Effect of Qinghuang Powder combined Chinese herbs for Pi-strengthening and Shen-reinforcing on HIF-1alpha in bone marrow mononuclear cells of myelodysplastic syndrome patients: an experimental research].
Gao F; Xu YG; Yang XH; Ma R
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2014 Feb; 34(2):174-8. PubMed ID: 24672941
[TBL] [Abstract][Full Text] [Related]
6. Association of Gene Mutations with Response to Arsenic-Containing Compound Qinghuang Powder () in Patients with Myelodysplastic Syndromes.
Zhao P; Liang JB; Deng ZY; Wang MJ; Qin JY; Chen CJ; Hu XM
Chin J Integr Med; 2019 Jun; 25(6):409-415. PubMed ID: 29619748
[TBL] [Abstract][Full Text] [Related]
7. [Effect of treatment for hypocellular myelodysplastic syndromes by a low dose qinghuang powder combined with Chinese drugs for Shen supplementing and Pi invigorating: a clinical observation].
Zhou QB; Wang HZ; Gao F; Tang XD; Xu S; Yang XH; Xu YG; Hu XM; Ma R
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2014 Dec; 34(12):1444-8. PubMed ID: 25632743
[TBL] [Abstract][Full Text] [Related]
8. Arsenic concentration in peripheral blood is correlated with efficacy of a Traditional Chinese Medicine regimen containing realgar for the treatment of myelodysplastic syndrome.
Wang DX; Xu YG; Du Y; Wang HZ; Li L; Hu XM; Yang XP; Ma R; Zhou QB
J Tradit Chin Med; 2021 Aug; 41(4):630-635. PubMed ID: 34392657
[TBL] [Abstract][Full Text] [Related]
9. Arsenic-Containing Qinghuang Powder () is an Alternative Treatment for Elderly Acute Myeloid Leukemia Patients Refusing Low-Intensity Chemotherapy.
Fan T; Quan RC; Liu WY; Xiao HY; Tang XD; Liu C; Li L; Lv Y; Wang HZ; Xu YG; Guo XQ; Hu XM
Chin J Integr Med; 2020 May; 26(5):339-344. PubMed ID: 31848890
[TBL] [Abstract][Full Text] [Related]
10. Comparing Arsenic-Containing Qinghuang Powder and Low-Intensity Chemotherapy in Elderly Patients with Acute Myeloid Leukemia.
Wu YH; Xiao HY; Quan RC; Tang XD; Liu WY; Lyu Y; Chen Z; Liu C; Hu XM
Chin J Integr Med; 2023 Sep; 29(9):832-837. PubMed ID: 37222831
[TBL] [Abstract][Full Text] [Related]
11. Arsenic disulfide induced apoptosis and concurrently promoted erythroid differentiation in cytokine-dependent myelodysplastic syndrome-progressed leukemia cell line F-36p with complex karyotype including monosomy 7.
Hu XM; Tanaka S; Onda K; Yuan B; Toyoda H; Ma R; Liu F; Hirano T
Chin J Integr Med; 2014 May; 20(5):387-93. PubMed ID: 24610410
[TBL] [Abstract][Full Text] [Related]
12. Clinical Response to Traditional Chinese Herbs Containing Realgar (As
Zhou QB; Du Y; Zhang SS; Liu ZT; Ma R; Xu YG
Cancer Manag Res; 2021; 13():55-63. PubMed ID: 33442294
[TBL] [Abstract][Full Text] [Related]
13. Anticoccidial Activity of Qinghao Powder Against
Wang L; Guo W; Haq SU; Guo Z; Cui D; Yang F; Cheng F; Wei X; Lv J
Front Vet Sci; 2021; 8():709046. PubMed ID: 34712720
[TBL] [Abstract][Full Text] [Related]
14. Clinical observation of the treatment of myelodysplastic syndrome mainly with Qinghuang Powder.
Xu S; Ma R; Hu XM; Xu YG; Yang XH; Wang HZ; Sun SZ; Liu F
Chin J Integr Med; 2011 Nov; 17(11):834-9. PubMed ID: 22057412
[TBL] [Abstract][Full Text] [Related]
15. Comparative health risk assessment of realgar and NiuHuangJieDu tablets based on tissue arsenic levels after multiple oral administration to rats.
Wu X; Guan R; Liu Y; Wu S; Song M; Hang T
J Ethnopharmacol; 2020 Mar; 249():112370. PubMed ID: 31683032
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of immunological changes following realgar and arsenic trioxide treatments in a murine model of myelodysplastic syndrome.
Tao Y; Xue T; Li X; Guo R; Wang Y; Xu H; Hu K; Dong X; Wang D; Ren J; Guan Y; Lu J
Immunopharmacol Immunotoxicol; 2024 Jun; 46(3):408-416. PubMed ID: 38816179
[TBL] [Abstract][Full Text] [Related]
17. Arsenic-Related Health Risk Assessment of Realgar-Containing NiuHuangJieDu Tablets in Healthy Volunteers
Wu X; Yan R; Guan R; Du Y; Liu Y; Wu S; Zhu S; Song M; Hang T
Front Pharmacol; 2021; 12():761801. PubMed ID: 35069195
[TBL] [Abstract][Full Text] [Related]
18. [Effects of qinghuang power combined Chinese herbs for shen reinforcing and Pi strengthening on activated T cells of myelodysplastic syndrome patients].
Gao F; Ma R; Yang XH; Xu YG
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Apr; 33(4):443-7. PubMed ID: 23841258
[TBL] [Abstract][Full Text] [Related]
19. Hematologic outcomes of myelodysplastic syndromes treatment with hypomethylating agents in community practice.
Bordoni RE; Feinberg BA; Gilmore JW; Haislip S; Jackson JH; Farrelly E; Kim E; Buchner D
Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):350-4. PubMed ID: 21816373
[TBL] [Abstract][Full Text] [Related]
20. Effects of Qinghuang Powder on Acute Myeloid Leukemia Based on Network Pharmacology, Molecular Docking, and In Vitro Experiments.
Zeng YJ; Wu M; Zhang H; Wu XP; Zhou L; Wan N; Wu ZH
Evid Based Complement Alternat Med; 2021; 2021():6195174. PubMed ID: 34992668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
